137225-13-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridinecarbonitrile,2-(methylamino)-(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of active pharmaceutical ingredients. Its unique structure allows for the creation of diverse drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Pyridinecarbonitrile,2-(methylamino)-(9CI) is utilized as a building block in the production of crop protection agents. Its incorporation into these agents can enhance their effectiveness in protecting crops from pests and diseases, thereby contributing to increased agricultural productivity.
Used in Dye Industry:
4-Pyridinecarbonitrile,2-(methylamino)-(9CI) is employed as a crucial component in the synthesis of various dyes. Its presence in these dyes can improve their colorfastness, brightness, and stability, making them suitable for a wide range of applications, including textiles, plastics, and printing inks.
Used in Materials Science and Research:
4-Pyridinecarbonitrile,2-(methylamino)-(9CI) also finds application in the field of materials science, where it can be used to develop new materials with unique properties. Additionally, 4-Pyridinecarbonitrile,2-(methylamino)-(9CI) serves as a valuable reagent in various chemical reactions, aiding researchers in their quest to discover new compounds and reactions with potential applications in various industries.

Upstream product

• 33252-30-1 2-chloro-4-pyridinenitrile 
• 74-89-5 methylamine 
• 3939-14-8 2-fluoropyridine-4-carbonitrile 

Downstream Products

• 618446-35-8 4-(aminomethyl)-N-methylpyridin-2-amine 
• 1016772-06-7 2-methylaminothioisonicotinamide 

Relevant academic research and scientific papers

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES

Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.

Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors

The Rho kinases (ROCK1 and ROCK2) are highly homologous serine/threonine kinases that act on substrates associated with cellular motility, morphology, and contraction and are of therapeutic interest in diseases associated with cellular migration and contraction, such as hypertension, glaucoma, and erectile dysfunction. Beginning with compound 4, an inhibitor of ROCK1 identified through high-throughput screening, systematic exploration of SAR, and application of structure-based design, led to potent and selective ROCK inhibitors. Compound 37 represents significant improvements in inhibition potency, kinase selectivity, and CYP inhibition and possesses pharmacokinetics suitable for in vivo experimentation.

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

Pyrid-2-one derivatives and methods of use

Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Substituted alkylamine derivatives and methods of use

Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.